Naloxone half-life
The model is tied to intranasal naloxone, whose terminal half-life is about two hours in labeling and contemporary review context.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Naloxone: evidence and interpretation notes
What the representative value means
The model is tied to intranasal naloxone, whose terminal half-life is about two hours in labeling and contemporary review context. Clinical response and recurrence of opioid toxicity depend on the opioid and patient, not this curve alone.
A 2-hour input gives this profile one auditable line for Intranasal naloxone. The line deliberately stops short of claims about clinical effect, measured concentration, or testing results.
Naloxone is included for public-health and emergency-literacy context. The curve can show short plasma persistence, but overdose response must follow product labeling and emergency medical guidance.
What each source contributes
- DailyMed: NALOXONE HYDROCHLORIDE SPRAY [BLUEPOINT LABORATORIES]. This product label adds formulation-specific pharmacokinetic context and does not represent every route or product.
- PubChem: Naloxone. This identity record confirms names and compound identity and does not supply a human half-life.
- Clinical Pharmacokinetics and Pharmacodynamics of Naloxone. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Naloxone, the numerical model is tied most closely to DailyMed: NALOXONE HYDROCHLORIDE SPRAY [BLUEPOINT LABORATORIES]. As a product label, it adds formulation-specific pharmacokinetic context; it does not represent every route or product.
Why there is no range on the chart
This profile plots 2 hours for Intranasal naloxone without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 2 h as a representative input for Intranasal naloxone. In the simplified model, about 0.0% remains after 24 hours and about 3% remains after five half-lives, or roughly 10 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
opioid antagonist context
Opioid antagonist interpretation depends on route, formulation, effect duration, and the clinical scenario, so half-life alone is an incomplete safety summary.
- The curve does not predict reversal duration or clinical outcomes.
- Route and formulation are central to source interpretation.
- Emergency and treatment decisions require qualified guidance.
ComparisonTimeline checkpoints and nearby profiles
Naloxone timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 12.5% | Long-tail portion of the model |
| 12 h | 1.56% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.02% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Naloxone within the opioid antagonist group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
No nearby published profiles are available in this category.
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 2 h |
|---|---|
| Modeled analyte or phase | Intranasal naloxone |
| Curve type | Normalized, first-order decline |
Selection note: The model is tied to intranasal naloxone, whose terminal half-life is about two hours in labeling and contemporary review context. Clinical response and recurrence of opioid toxicity depend on the opioid and patient, not this curve alone.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Official labeling DailyMed label: NALOXONE HYDROCHLORIDE SPRAY [BLUEPOINT LABORATORIES].Official U.S. product labeling used for formulation and labeled pharmacokinetic context; its statements apply to the described product.
- Identity record PubChem Compound Summary: Naloxone.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Clinical Pharmacokinetics and Pharmacodynamics of Naloxone.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the opioid-antagonist group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.